Brolucizumab is a prescription medicine indicated for the treatment of bEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of, among other approved uses. It is available as injection for intravitreal use. MedsAcross supplies Brolucizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD). Diabetic Macular Edema (DME)
Source: US FDA prescribing information
Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110, VEGF 121, and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.
Source: US FDA prescribing information
Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks. Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks.
Source: US FDA prescribing information
Ocular or Periocular Infections. Active Intraocular Inflammation. Hypersensitivity Ocular or Periocular Infections BEOVU is contraindicated in patients with ocular or periocular infections.
Source: US FDA prescribing information
Endophthalmitis and retinal detachment may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay. Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay. Increases in intraocular pressure (IOP) have been seen within 30 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors.
Source: US FDA prescribing information
The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Endophthalmitis and Retinal Detachment Retinal Vasculitis and/or Retinal Vascular Occlusion Increase in Intraocular Pressure Thromboembolic Events The most common adverse reactions reported in patients receiving BEOVU are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters.
Source: US FDA prescribing information
Refrigerate BEOVU between 2°C to 8°C (36°F to 46°F). Do not freeze. Prior to use, the unopened glass vial or sealed blister pack of BEOVU may be kept at room temperature, 20°C to 25°C (68°F to 77°F) for up to 24 hours. Store BEOVU in the outer carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Brolucizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Beovu 6 mg/0.05 mL injectionIntravitreal Cold chain | Novartis Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Brolucizumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Brolucizumab, including Beovu.
Yes. The US FDA first approved Brolucizumab on 7 October 2019, according to Drugs@FDA.
Yes. Brolucizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Brolucizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Brolucizumab is classified under ATC code S01 (Eye medicines).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.